Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P0DN86: Variant p.Asp137Ala

Choriogonadotropin subunit beta 3
Gene: CGB8
Feedback?
Variant information Variant position: help 137 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Alanine (A) at position 137 (D137A, p.Asp137Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 137 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 165 The length of the canonical sequence.
Location on the sequence: help TTDCGGPKDHPLTCDDPRFQ D SSSSKAPPPSLPSPSRLPGP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 21 – 165 Choriogonadotropin subunit beta 3
Region 131 – 165 Disordered
Glycosylation 141 – 141 O-linked (GalNAc...) serine
Glycosylation 147 – 147 O-linked (GalNAc...) serine
Glycosylation 152 – 152 O-linked (GalNAc...) serine



Literature citations
Evolution of the genes for the beta subunits of human chorionic gonadotropin and luteinizing hormone.
Talmadge K.; Vamvakopoulos N.C.; Fiddes J.C.;
Nature 307:37-40(1984)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT ALA-137; The beta subunit of human chorionic gonadotropin is encoded by multiple genes.
Policastro P.; Ovitt C.E.; Hoshina M.; Fukuoka H.; Boothby M.R.; Boime I.;
J. Biol. Chem. 258:11492-11499(1983)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS MET-24 AND ALA-137; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANTS LEU-4 AND ALA-137; Chorionic gonadotropin has a recent origin within primates and an evolutionary history of selection.
Maston G.A.; Ruvolo M.;
Mol. Biol. Evol. 19:320-335(2002)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 6-164; VARIANTS ALA-18; ARG-22; MET-24; TRP-28; HIS-30; ILE-35; ALA-137 AND CYS-147; MISCELLANEOUS;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.